Beijing Luzhu Biotechnology Co Ltd
HKEX:2480
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Beijing Luzhu Biotechnology Co Ltd
Change in Working Capital
Beijing Luzhu Biotechnology Co Ltd
Change in Working Capital Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Change in Working Capital | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
B
|
Beijing Luzhu Biotechnology Co Ltd
HKEX:2480
|
Change in Working Capital
¥42.9m
|
CAGR 3-Years
179%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Beigene Ltd
HKEX:6160
|
Change in Working Capital
-¥17.7B
|
CAGR 3-Years
-22%
|
CAGR 5-Years
-137%
|
CAGR 10-Years
N/A
|
|
|
Innovent Biologics Inc
HKEX:1801
|
Change in Working Capital
-¥315.4m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
8%
|
CAGR 10-Years
N/A
|
|
|
RemeGen Co Ltd
SSE:688331
|
Change in Working Capital
-¥2.3B
|
CAGR 3-Years
-24%
|
CAGR 5-Years
-83%
|
CAGR 10-Years
N/A
|
|
|
Akeso Inc
HKEX:9926
|
Change in Working Capital
¥170.7m
|
CAGR 3-Years
28%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
S
|
Sichuan Kelun-Biotech Biopharmaceutical Co Ltd
HKEX:6990
|
Change in Working Capital
-¥115.3m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Beijing Luzhu Biotechnology Co Ltd
Glance View
Beijing Luzhu Biotechnology Co., Ltd. engages in the development, production, and sale of active pharmaceutical ingredients. The company is headquartered in Beijing, Beijing. The company went IPO on 2023-05-08. The firm is also engaged in out-licensing human vaccines and therapeutic biologics. Its products under clinical development include recombinant herpes zoster vaccine LZ901, and antibody injection products K3 and K193. Its LZ901 is mainly used to prevent herpes zoster caused by varicella zoster virus in adults aged 50 and above. The firm operates in the domestic market and overseas markets.
See Also
What is Beijing Luzhu Biotechnology Co Ltd's Change in Working Capital?
Change in Working Capital
42.9m
CNY
Based on the financial report for Dec 31, 2024, Beijing Luzhu Biotechnology Co Ltd's Change in Working Capital amounts to 42.9m CNY.
What is Beijing Luzhu Biotechnology Co Ltd's Change in Working Capital growth rate?
Change in Working Capital CAGR 3Y
179%
The average annual Change in Working Capital growth rates for Beijing Luzhu Biotechnology Co Ltd have been 179% over the past three years .
